Twareat Medical Care Co. Announces the Results of the Ordinary General Assembly Meeting (First Meeting)

Twareat Medical Care Co. shareholders approved the 2025 financial statements, the Board of Directors' report, and the discharge of Board members from liability for the fiscal year ended December 31, 2025.
The Board of Directors received authorization to distribute interim dividends to shareholders on a semi-annual or quarterly basis for the 2026 fiscal year.
Shareholders approved the appointment of BDO Dr. Mohamed Al-Amri & Co. as the company's auditor for the 2026 fiscal year and Q1 2027, with total fees set at SAR 530,000.
Approval was granted for related party contracts with Urgent Care Pharmacy Company for the purchase of medical supplies, with an expected annual transaction value of SAR 1 million.

Element List	Explanation
Introduction	The Board of Directors of Twareat Medical Care Co. is pleased to announce the results of the Ordinary General Assembly Meeting (First Meeting), which was held at 8:05 pm on Tuesday,15/01/1448H corresponding to 30/06/2026G, where the meeting was held remotely, using modern technology, after the quorum of the meeting was completed.
City and Location of the General Assembly's Meeting	Via modern technology (remotely) at the company's headquarters in Al Khobar.
Date of the General Assembly's Meeting	2026-06-30 Corresponding to 1448-01-15
Time of the General Assembly’s Meeting	20:05
Percentage of Attending Shareholders	83.07%
Names of the Board of Directors' Members Present at the General Assembly's Meeting and Names of the Absentees	The members of the Board of Directors attended the General Assembly meeting: Mr. Amer Mohammed Amer Al Amer - Chairman. Dr. Tariq Mohammed Sulaiman Al-Hamdan Vice Chairman. Mr. Raed Mohammed Abdullatif Al-Naeem - Member. Dr. Khalid Mohammed Sulaiman Al-Hamdan - Managing Director & CEO. Mr. Faisal Abdullah Mohammed Al-Qahtani – Member. Mr. Abdullah Mohammed Sulaiman Al-Hamdan - Member. Mr. Mohamed Ahmed Rumizan Al-Rumizan – Member. Mr. Hani Mohammed Abdulrahman Al-Hashemi – Member. Apology received from: Mr. Saleh bin Mohammed Al-Mulhim – Member.
Names of the Chairmen of the Committees Present at the General Assembly's Meeting or Members of such Committees Attending on Their Behalf	Mr. Raed bin Mohammed Al-Naeem – Chairman of the Audit Committee. Dr. Tariq Mohammed Sulaiman Al-Hamdan – Chairman of the Executive Committee.
Voting Results on the Items of the General Assembly's Meeting Agenda's	1- The Board of Directors' report for the fiscal year ended 31/12/2025 was reviewed and discussed. 2- The Company's financial statements for the financial year ended 31/12/2025 was reviewed and discussed. 3. The auditor's report for the financial year ended 31/12/2025 was approved after discussion. 4. Approval of appointing BDO Dr. Mohamed Al-Amri & Co. as auditor for the company from among the candidates based on the recommendation of the Audit Committee, to examine, review and audit the financial statements for the second and third quarters of 2026, the annual financial statements ended on 31/12/2026, and the financial statements for the first quarter of 2027, with total fees of SAR 530,000 (VAT excluded). 5. Approval of the discharge of the members of the Board of Directors for the financial year ending on 31/12/2025. 6. Approval of authorizing the Board of Directors to distribute interim dividends to shareholders on a semi- or quarterly basis for the financial year ending 31 December 2026. 7- Approval of the works and contracts that will be executed between the company and the Urgent Care Pharmacy Company, in which the member of the Board of Directors (Dr. Tariq Mohammed Sulaiman Al-Hamdan in his capacity as Vice Chairman of the Board of Directors) has a direct interest, which is the sale/purchase of medicines, supplies, medical devices and mobile clinics without preferential conditions with an expected annual amount of one million riyals for a calendar year, noting that the value of transactions for the previous year is 87,347 Saudi riyals. 8. Approval of authorizing the Board of Directors with the authority of the Ordinary General Assembly to license stipulated in paragraph (1) of Article Twenty-Seven of the Companies Law, for a period of one year from the date of approval of the General Assembly or until the end of the session of the delegated Board of Directors, whichever is earlier, in accordance with the conditions outlined in the Executive Bylaws of the Companies Law for listed joint stock companies. 9. Approval of the credit risk policy and the provision for expected credit losses. 10. Approval of amending the remuneration policy and standards of the members of the Board of Directors, its subordinate committees, and the Executive Management.
Additional Information	The Board of Directors of Twareat Medical Care Co. would like to thank all the respected shareholders for their participation and attendance on the Ordinary General Assembly meeting (first meeting).